新华社北京1月5日电 题：长江母亲河重新焕发生机活力——国新办发布会聚焦长江经济带发展十 年成效 新华社记者高敬、张晓洁 长江经济带发展是我国区域重大战略。2016年1月5日，习近平总书记在重庆召开推动长江经济带发 展座谈会，提出"共抓大保护，不搞大开发"的明确要求。国务院新闻办公室5日举行新闻发布会，介绍 长江经济带发展十年工作进展和成效。 国家发展改革委副主任王昌林表示，十年来，长江经济带优良水质比例从67%提升到96.5%，地区 生产总值翻了一番多、占全国比重从42.2%提升到47.3%，绘就了人与自然和谐共生的中国式现代化的 长江画卷。 生态长江底色更加鲜明 十年来，生态长江底色更加鲜明。生态环境部水生态环境司司长蒋火华介绍，长江干流连续6年保 持Ⅱ类水质，江豚等旗舰物种数量增加。生态环境部与沿江省市和有关部门一道深入打好长江保护修复 攻坚战—— 入河排污口是污染物进入水体的最后一道"闸门"。蒋火华表示，"十四五"期间，累计排查长江河湖 岸线16万多公里，20多万个入河排污口精准"落户"，重要河湖的排污口排查整治率超过90%。 长江十年禁渔已实施满五年。农业农村部长江流域渔政监督管理办公室主任江开勇介 ...

Core Viewpoint - The Shanxi Provincial Department of Commerce and the Shanxi Provincial Department of Industry and Information Technology have jointly announced the second batch of provincial-level characteristic consumer goods parks, with the Gaoping Economic and Technological Development Zone's food consumer goods park successfully selected [1][9]. Group 1: Announcement Details - The announcement was made on December 30, 2025, and is part of a broader initiative to promote characteristic consumer goods parks in Shanxi Province [3]. - A total of 12 parks were selected, focusing on key consumer goods sectors such as pharmaceuticals, food, beverages, ceramics, and kitchenware [7][16]. Group 2: Gaoping Economic and Technological Development Zone - The Gaoping Economic and Technological Development Zone's food consumer goods park includes areas of the Sanjia Industrial Park and Taiwan Industrial Park, featuring a central factory project capable of producing 3 million frozen desserts daily [5][13]. - The park has attracted companies like Xiapusair, Jinbao Green Treasure, and Fresh Bread, establishing a collaborative development model of "leading enterprises + supporting enterprises" [5][13]. - By 2025, the total output value of enterprises within the park is projected to reach 660 million yuan [5][13]. Group 3: Development Strategy - The selected parks aim to leverage regional resources and industrial foundations to create characteristic industrial clusters through models like "parks within districts" and "parks within towns" [16]. - These parks will benefit from policy support and funding, enhancing the resilience of the industrial chain and local supply rates, thereby boosting the overall competitiveness of Shanxi's consumer goods industry [7][16].

Core Insights - In 2025, approximately 75 actively managed equity funds achieved a net value increase of over 100%, but there was significant disparity, with several funds reporting negative returns exceeding 10% [2][8] - Among the underperformers, six funds from GF Fund were highlighted, all managed by Wang Mingxu, indicating a potential issue with his management strategy [2][8] Fund Performance Analysis - Wang Mingxu managed a total of eight funds, with six showing negative annual returns, including the flagship fund, GF Domestic Demand Growth, which reported a -16.31% return for the year [10] - The fund underwent a significant style shift in its holdings throughout 2025, moving from a focus on real estate, liquor, and banking stocks in Q1 to a more diversified approach in Q2, yet the results remained unsatisfactory [3][11] Managerial Challenges - Wang Mingxu's management faced criticism as his long-held fund, GF Domestic Demand Growth, became a significant underperformer despite his overall fund management experience and a reported best-term return of 115.25% [10] - The fund's quarterly reports indicated attempts to adjust the portfolio by selling overvalued stocks and increasing positions in high-end liquor and IT services, but these adjustments did not yield the desired improvement in performance [4][11] Performance of Other Managers - Zheng Chengran, another manager at GF Fund, also faced challenges, with his funds showing a wide performance range; one fund achieved over 70% returns while five others fell below 20% [5][12] - His investment strategy included a mix of sectors that did not align with his expertise, leading to underwhelming results, particularly in the healthcare and steel sectors [12]

Group 1 - Ugreen Technology expects a net profit of 653 million to 733 million yuan for 2025, representing a year-on-year growth of 41.26% to 58.56% [1] - SenTai Co. plans to invest no more than 140 million yuan to establish a production base in Vietnam [2] - Muyuan Foods reported a December 2025 sales revenue of 9.667 billion yuan from commodity pigs, a year-on-year decline of 36.06% [3] Group 2 - Pumen Technology has received a medical device registration certificate for a quality control product used in various cancer markers [4] - Heng Rui Medicine's subsidiary has received approval for clinical trials of two injection drugs targeting obesity [5] - Quartz Co. was fined 2.7 million yuan for commercial secret infringement by its subsidiary [6] Group 3 - Chifeng Gold expects a net profit of 3 billion to 3.2 billion yuan for 2025, an increase of approximately 70% to 81% year-on-year [7] - Fulong Technology has terminated the transfer of 82.0969 million shares [8] - Senba Sensor's actual controller has released the pledge of 16.48 million shares [9] Group 4 - Hanma Technology reported a cumulative truck sales increase of 58.45% for 2025 [12] - Guankang Clean won a bid for a special procurement project worth 157 million yuan [14] - Defu Technology signed a cooperation agreement for high-end copper foil supply with a leading CCL company [15] Group 5 - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology [16] - CanSino received approval for clinical trials of a 24-valent pneumococcal polysaccharide conjugate vaccine [17] - Yipin Hong's subsidiary received approval for a supplementary application for oseltamivir phosphate capsules [19] Group 6 - Taotao Vehicle expects a net profit of 800 million to 850 million yuan for 2025, a year-on-year increase of 85.50% to 97.10% [20] - Yutong Bus reported a cumulative sales increase of 5.54% for 2025 [21] - Kingoo Co. received a notification from VinFast to supply automotive wheel products [22] Group 7 - ST Renfu's subsidiary received approval for clinical trials of a new drug for late-stage solid tumors [23] - Nanxing Co. expects a net profit of 90 million to 120 million yuan for 2025, reversing a loss from the previous year [24] - Jinrui Mining's subsidiaries will undergo routine maintenance starting January 5, 2026 [25] Group 8 - Changjiang Power reported a 3.82% increase in total power generation for its six hydropower stations in 2025 [26] - David Medical's subsidiary received a medical device registration certificate for an electronic endoscope image processor [28] - Guiguan Power reported a 26.68% increase in cumulative power generation for 2025 [29] Group 9 - ShenNan Electric's subsidiary won a project worth 208 million USD for a power plant operation service [30] - ST Kaiyuan's major shareholder's shares will be auctioned [31] - Jiecheng Co.'s major shareholder's shares have been auctioned [32] Group 10 - Tongbao Energy's wind power project has begun generating electricity [33] - Xusheng Group received an order worth 7.8 billion yuan from a North American EV manufacturer [34] - Qianli Technology reported a 154.08% increase in December 2025 electric vehicle production [35] Group 11 - Chint Electric plans to issue H-shares and list on the Hong Kong Stock Exchange [36][37] - Whirlpool expects a net profit increase of approximately 150% for 2025 [38] - Yongjie New Materials signed a 2 billion yuan aluminum alloy procurement contract [39]

科创综指成新质生产力定价新锚，指数中电子、医药、计算机机械设备等前四大行业是硬科技的核心载 体，那么，2026年四大行业的增长驱动因素有何差异？申万宏源首席电子分析师杨海晏表示，2026年投 资核心趋势聚焦AI行业从资本开支与模型训练驱动，转向商业化变现能力的关键转变，这一转变关乎 AI行业长远发展及商业模式闭环形成，将带动软件、硬件、电子科技、通信、计算机等多领域受益。 ...

Market Overview - The Shanghai Composite Index closed at 4023.42 points, above the annual line, with a gain of 1.38% [1] - The total trading volume of A-shares reached 30,483.30 billion yuan [1] Stocks Breaking Annual Line - A total of 204 A-shares have surpassed the annual line today, with notable stocks including: - Guanhao Biological (300238) with a deviation rate of 13.10% - Beilu Pharmaceutical (300016) with a deviation rate of 12.97% - Yinkang Life (300143) with a deviation rate of 12.90% [1] Stocks with Significant Deviation Rates - Stocks with high deviation rates include: - Guanhao Biological: 20.00% increase, latest price at 16.62 yuan - Beilu Pharmaceutical: 13.22% increase, latest price at 8.99 yuan - Yinkang Life: 15.18% increase, latest price at 11.38 yuan [1] Additional Stocks with Positive Performance - Other stocks showing positive performance include: - Gangtong Medical (301515) with a 14.16% increase and a deviation rate of 12.82% - Zhite New Materials (300986) with a 20.04% increase and a deviation rate of 10.50% [1] Stocks with Lower Deviation Rates - Stocks that have just crossed the annual line with lower deviation rates include: - Longqi Technology (603341) with a 10.01% increase and a deviation rate of 9.02% - Taihe New Materials (002254) with a 9.98% increase and a deviation rate of 8.61% [1]

Core Viewpoint - Daiwa has released a report recommending specific pharmaceutical stocks, highlighting the preference for Innovent Biologics (01801) and Hengrui Medicine (600276.SH) while maintaining a "sell" rating on CSPC Pharmaceutical Group (01093) [1] Group 1: Stock Recommendations - Innovent Biologics' target price has been raised from HKD 95 to HKD 112 [1] - Hengrui Medicine's target price remains at RMB 80 [1] - CSPC Pharmaceutical Group's target price is maintained at HKD 6.6 with a "sell" rating [1] Group 2: Market Outlook - The Chinese biopharmaceutical sector is expected to experience a comprehensive increase in 2025 [1] - For 2026, Daiwa suggests a more selective stock-picking strategy focusing on high-quality targets [1] Group 3: Key Focus Areas for 2026 - Daiwa plans to outline key clinical data release timelines [1] - The report will identify significant stock price catalysts [1] - Key areas of analysis will include PD-(L)1/VEGF, GLP-1, and siRNA [1]

Core Viewpoint - Daiwa has released a report recommending specific pharmaceutical stocks, highlighting Innovent Biologics (01801) and Heng Rui Medicine (600276) as top picks, with target price adjustments and ratings for other companies in the sector [1] Company Recommendations - Innovent Biologics' target price has been raised from HKD 95 to HKD 112 [1] - Heng Rui Medicine's target price remains at RMB 80 [1] - CSPC Pharmaceutical Group (01093) is rated "Sell" with a target price maintained at HKD 6.6 [1] Industry Outlook - The Chinese biopharmaceutical sector is expected to experience a comprehensive increase in 2025 [1] - For 2026, Daiwa suggests a more selective stock-picking strategy focusing on high-quality targets [1] - Key clinical data release timelines and significant stock price catalysts will be outlined for 2026 [1] - Important areas of analysis include PD-(L)1/VEGF, GLP-1, and siRNA [1]

Group 1 - The A-share market is currently undergoing adjustments, with a focus on the recovery of trading activity after a period of rotation in market trends since November [1] - The trading activity has decreased from a high of 12% in October to around 10% recently, indicating a potential consolidation phase in the coming month [1] - The top five sectors with net inflows include semiconductors, new energy vehicles, pharmaceuticals, lithium batteries, and domestic software [1] Group 2 - Financial statistics indicate stable overall entity financing, with a notable divergence in credit structure; corporate loans and bond financing have improved, while household financing remains weak [3] - The central economic work conference has outlined a direction for fiscal and investment support, creating a favorable environment for banks to expand balance sheets and provide long-term loans [3] - Fourteen listed companies are entering the restructuring phase, with significant risks of stock price declines due to capital reserve transfers during the restructuring process [3] Group 3 - The domestic industrial products market shows no significant improvement in fundamentals, but low valuations present potential risks for short selling [5] - The Hong Kong stock market is viewed as a value trap due to multiple supporting factors, including policy support and valuation advantages [5] - The REITs market is expanding with innovative products across various sectors, becoming an important vehicle for capital markets to support the real economy [5] Group 4 - The Shanghai Composite Index is entering a year-end rally, with expectations for a continued upward trend despite potential short-term corrections [9] - The technology sector is experiencing downward pressure due to high valuations and corrections in U.S. AI leading stocks, impacting the A-share market [9] - The ChiNext Index is expected to reach new highs in January, but many individual stocks are only experiencing slight increases, highlighting the importance of selecting the right direction and targets [9]

2026年首个交易日，A股主要股指高开高走，沪指涨超1%重返4000点上方，创业板指涨近3%，科创50 指数大涨超4%。 盘面上看，保险、半导体、医药、有色等板块走强，券商、地产、石油、酿酒等板块上扬，人脑工程概 念爆发，存储芯片、创新药、AI应用概念等活跃。 中信证券认为，2026年最大的预期差来自于外需与内需的平衡，对外"征税"、补贴内需应是大势所趋， 今年是个重要的开端。站在开年，考虑到去年末的资金热度并不算高，人心思涨的环境下开年后市场震 荡向上的概率更高。前期共识性品种"调整后再上车"大概率是机构资金主要的考虑方向，例如有色、海 外算力、半导体自主可控等，当然有些偏游资风格的品种也属于这一类别，比如商业航天、机器人等。 反共识品种是一些配置型增量资金的考虑，典型的方向就是通过内需消费的小仓位增配去捕捉年内的超 预期政策变化，免税、航空等出行服务相关的行业应该是增量布局重点，优质的地产开发商也是考虑对 象。 （文章来源：证券时报网） 截至收盘，沪指涨1.38%报4023.42点，深证成指涨2.24%，创业板指涨2.85%，科创50指数涨4.4%，沪 深北三市合计成交25674亿元。 ...